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ABSTRACT: Animal venoms can play an important role in
drug discovery, as they are a rich source of evolutionarily
tuned compounds that target a variety of ion channels and
receptors. To date, there are six FDA-approved drugs derived
from animal venoms, with recent work using high-throughput
platforms providing a variety of new therapeutic candidates.
However, high-throughput methods for screening animal
venoms against purinoceptors, one of the oldest signaling
receptor families, have not been reported. Here, we describe a
variety of quantitative fluorescent-based high-throughput
screening (HTS) cell-based assays for screening animal
venoms against ligand-gated P2X receptors. A diverse
selection of 180 venoms from arachnids, centipedes,
hymenopterans, and cone snails were screened, analyzed,
and validated, both analytically and pharmacologically. Using this approach, we performed screens against human P2X3, P2X4,
and P2X7 using three different fluorescent-based dyes on stable cell lines and isolated the active venom components. Our HTS
assays are performed in 96-well format and allow simultaneous screening of multiple venoms on multiple targets, improving
testing characteristics while minimizing costs, specimen material, and testing time. Moreover, utilizing our assays and applying
them to the other natural product libraries, rather than venoms, might yield other novel natural products that modulate P2X
activity.
Natural products have a storied past as drug leads, with anestimated half of the top-selling drugs in the world
originating from a natural product.1 Among them, animal
venoms are no exception. Several research groups consider
toxins from spiders,2,3 cone snails,4 snakes,5 sea anemones,6,7
jellyfishes,8 and scorpions9 as a reliable animal source to
engage in therapeutic lead discovery. The underlying reason
for this trend is that venoms offer a diversity of molecules that
modulate a wide range of ion channels with high affinity and
selectivity.10 However, the biochemical arsenal of these
venomous creatures has barely been tapped due to biological,
historical, technological, and even practical reasons.11
Fortunately, modern venom research is leveraging the recent
revolution in high-throughput approaches in genomics,
transcriptomics, proteomics, and metabolomics. The con-
fluence of these technologies with advances in bioinformatics
offers exciting new possibilities to exploit the remarkable
chemical diversity of nature’s pharmacopeia in the quest for
new drugs. While most of the six venom-derived drugs
currently on the market have been developed from snakes,10
which yield large amounts of venom, the rapid progress in
high-throughput screening (HTS) now enables efficient
screening of venoms from animals that previously could not
be studied because they yield only small amounts of venom.11
Still, many venoms have not been studied with respect to
potential biological targets. In large part, this bottleneck is due
to the fact that the development of robust HTS assays that
could access this uncharted chemical space and determine the
molecular targets of venom toxins is often a major challenge.12
Although ion channels are the third most common target of
small-molecule drugs after kinases and G-protein-coupled
receptors (GPCRs),13 they can be difficult targets to
investigate using HTS approaches,14 in part due to the lack
of high-throughput electrophysiological platforms for the
characterization of compound activity. Although manual
patch-clamp electrophysiological approaches are extremely
information-rich, they are labor intensive, represent a challenge
with regard to reproducibility of the cells being used, require
highly skilled staff, and can only support the evaluation of small
numbers of compounds. Consequently, HTS-based method-
ologies that use cell-based assays with membrane potential
dyes, Ca2+-sensitive dyes, or ion-flux measurements have
become integral components of ion-channel drug discovery
programs.15 While it would have been irrational to expect HTS
to directly deliver new molecular entities (NME) from a
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synthetic library, natural product libraries can be viewed as a
population of structurally privileged NME selected by
evolutionary pressures. By accessing their uncharted chemical
space, HTS might inspire more rapid discoveries.16,17 Taken
together with the unrealized potential of venoms, these natural
products might be of renewed interest as a source of chemical
diversity, HTS hit identification, and lead generation.16
Despite the current resurgence in the use of venoms as tools
in biomedical research, purinergic receptors have been largely
ignored in the quest for new toxins that modulate ligand-gated
channels. The only study that explored whether venoms are
capable of targeting purinergic receptors was from Grishin et
al.,2 who reported a potent and selective peptidic modulator of
human P2X3 from the venom of a wolf spider (family
Lycosidae). In addition to the established role of the P2X3
receptor in chronic pain,18 the purinergic P2X-mediated
system has been implicated in a wide range of disorders
including hypertension,19 bladder incontinence,20 chronic
cough,21 inflammatory and immune disorders,22 migraine,23
pain,24 irritable bowel syndrome,25 epilepsy,26 atherosclero-
sis,27 depression,28 diabetes,29 and cancer. However, we still
continue to fall short in addressing the increasing need for
novel, effective, safe, and well-tolerated treatments for these
conditions, despite decades of innovation and effort in the
purinergic field. To bridge this gap between the exciting
progress that has been made in pursuit of P2X-targeted drugs
for clinical development, we believe animal venoms might help
populate unmet pharmacological space. Taken together with
the need for high-quality HTS assays, we set out to develop a
venom screen toward various P2X receptors that would be
easily automated, fast, reliable, and robust and provide a
quantitative output that correlates well with the validated data.
Here, we report the design and development of three
fluorescent-based high-throughput cell assays that can be
used to screen animal venoms, or indeed other natural product
sources, against the human purinergic receptors hP2X3,
hP2X4, and hP2X7. These assays enable screening of multiple
venoms against multiple targets, improving testing character-
istics while minimizing costs, specimen material, and testing
time. Moreover, application of our assay to other venom
libraries or other natural products libraries might yield novel
drug entities with P2X activity and thus promote the discovery
of therapeutically beneficial agents for a variety of pathologies.
■ RESULTS AND DISCUSSION
Assay Design. To develop heterologous expression
systems for direct investigation of P2X modulation in adherent
cell cultures, we chose 1321N1 and HEK293 cell lines.
Previous screens designed to detect P2X activity against a
background of endogenous, high-level promiscuous P2Y
GPCR expression are often susceptible to artifacts or false
positives derived presumably from P2Y cell-surface receptors
hijacking P2X calcium signaling. Since the human astrocytoma
cell line 1321N1 possesses no endogenous P2 receptors that
might interfere with calcium signaling, we chose it as a suitable
cell line for our studies. Additionally, we previously used stable
HEK293 cell lines expressing hP2X4 or hP2X7 receptors to
perform the preliminary fluorescent-based cell assays and
successfully identified selected ginsenosides as novel allosteric
modulators of the purinergic receptor family.30 A similar
research effort was focused on other P2X receptors.31
While these assays represent a good starting point to screen
for potent P2X modulators, we still lack HTS that have been
rigorously validated for analytical and biochemical relevance,
especially when subjected to another class of natural products
such as venoms. In order to streamline our HTS workflow and
Figure 1. High-throughput screen of crude venoms against P2X receptors. (A) Crude venom (150 μL at a concentration of 1 g/L) is added to wells
of a 96-well plate, then screened in triplicate using different fluorescent dyes (Fura-2-AM, YO-PRO-1, and FLIPR Calcium-6 assay) against
1321N1-hP2X4, HEK293-hP2X7, and HEK-hP2X3 stable cell lines. (B) Venoms identified as hits in the initial assay are fractionated using reverse-
phase (RP) HPLC; then the fractions are screened in the HTS assays against the various P2X receptors to identify “hit” fractions with P2X activity.
(C) Hit fractions identified are further fractionated using orthogonal chromatography techniques to identify the bioactive compound, which is then
analyzed using mass spectrometry (MALDI-TOF, LC-MS, MS/MS). The toxin hit is then pharmacologically validated using two stable cell lines
expressing the P2X receptor of interest.
Journal of Natural Products Article
DOI: 10.1021/acs.jnatprod.9b00410
J. Nat. Prod. 2019, 82, 2559−2567
2560
apply our assays to the growing field of venomics,11 we have
developed high-quality HTS assays that would selectively
detect toxin hits from different animal venoms toward stably
expressed P2X channels. Figure 1 displays the screening and
fractionation workflow that was developed to enable rapid
interrogation of both crude venoms and semipure venom
fractions. The general scheme involves the following steps: (A)
fluorescent-based assays of crude venoms to identify “hits”; (B)
fractionation of venoms and toxin hit identification; (C) toxin
hit validation via a Flexstation 3 multimode plate reader to
collect information about the calcium/dye flux in each well of a
microplate simultaneously capturing the response kinetics of
the P2X channel.32
Overall, this scheme proved to be robust and easy to
implement. We measured fluorescence from the bottom of the
well to reduce background fluorescence, although this requires
that the cells are firmly adhered. If the cells detach or move
during liquid addition, the signal is compromised.32 Thus, we
developed stable adherent cell lines by transfecting 1321N1
and HEK293 cell lines with hP2X4 and hP2X7 plasmids:
1321N-hP2X4, HEK293-hP2X4, and HEK293-hP2X7.33 A
plethora of assay formats have been enabled to support
compound screening;34 however, we chose the 96-well plate
format and evaluated hP2X4 and hP2X7 inhibition with Fura-
2-AM and YOPRO-1 fluorescent dyes, respectively. By
quantifying either agonist (ATP)-mediated increases in
cytosolic Ca2+ concentrations (with Fura-2-AM) or dye uptake
(with YOPRO-1), we monitored relative changes in the levels
of intracellular Ca2+ or dye uptake in real time.
Assay Optimization. In developing the assays in a 96-well
format, systematic variation in assay parameters led to the
following optimal conditions that are outlined in the
Experimental Section. Critically, the calcium-sensitive fluo-
rescent dye Fura-2-AM and dye uptake probe YOPRO-1 utilize
different incubation buffers. Whereas the Fura-2 assay on
1321N1-hP2X4 requires a medium containing calcium, the
YOPRO uptake assay buffer is devoid of Mg2+ ions and
contains a very low concentration of Ca2+ ions since these ions
are known to inhibit hP2X7 pore formation.35 Since the real
power of such in vitro assays lies in the possibility to perform
high-throughput experiments, we decided to optimize our
assay conditions for inhibition evaluation and identification
studies. To determine whether our assays are pharmacologi-
cally predictive for P2X targets and capable of identifying
inhibitors with the desired potency and mechanism of action,
we systematically tested several commercially available small-
molecule inhibitors of hP2X4 (BX430, 5-BDBD, PSB12062)
and hP2X7 (AZ10606120). As a proof of principle, we
screened each compound at various concentrations and
generated concentration−response curves (Figure S1 in the
Supporting Information). Either cells were preincubated with
compounds for 10 min or antagonists or mock medium
(buffer) was applied onto them via Flexstation 3 automated
injection. The IC50 values we calculated for BX430, 5-BDBD,
PSB12062, and AZ10606120 using this assay mostly
corresponded well with reported potencies (Table 1);35−38
however, some IC50 values for 5-BDBD and PSB12062, in
HEK293-hP2X4 and 1321N1-hP2X4, respectively, differed
nearly 8-fold. This may be due to the assessment of IC50 values
that were independently measured in different laboratories
with different sets of assays.35−38 Ideally, IC50 values should be
compared only under similar conditions since these values are
often assay-specific.39
Based on these results, we chose BX430 and AZ10606120 as
positive controls for the hP2X4 and hP2X7 assays, respectively,
and utilized 10 μM concentrations throughout our studies.
Critically, when these inhibitors were preincubated and the
assay incubation time exceeded 60 min, these two inhibitors
less effectively inhibited the P2Xs. Thus, screens were limited
to <60 min. Moreover, cytotoxicity complications in assays
that require long incubation periods are inevitable and in many
cases can only be addressed by changing the assay
configuration from preincubation.32 For this reason, the
venoms (or inhibitors) were applied on top of the cells (or
preincubated) after 30 s prior to injection of agonist (ATP) at
100 s. This incubation time of 70 s allowed inhibitors a
sufficient time to inhibit either hP2X4 or hP2X7. We then
monitored the fluorescent responses for a further 200 s per
well. This result emphasizes the importance of assay
optimization via pilot screens.
Screen of Animal Venoms against hP2X4. Once these
conditions were defined, we proceeded into larger-size
libraries, such as venoms, to ensure assay performance. For
our typical crude venom screen, arranged in 96-well format,
crude venoms were dissolved in water and diluted up to 25-
fold from a stock solution of 1 g/L into the 96-well assay plate.
In the HTS assays, outlined in Figure 1, toxins are not
preincubated in discrete wells but are applied directly onto
cells as previously discussed.
In total, 180 crude venoms (for details see Table S1 in the
Supporting Information) from arachnids, centipedes, hyme-
nopterans, and cone snails were arranged in standard 96-well
drug plates and tested in duplicates. A subset of venoms were
tested for dose-dependent effects in triplicates (10, 2, or 0.4 μg
per well). Usually, chemical libraries are stored in organic
solvents such as EtOH or DMSO41 and assays need to be
configured so they are not sensitive to the concentration of
these solvents. In contrast, the venoms (and later the
fractionated toxins) were all dissolved in incubation buffer
(see the Experimental Section), and thus the solvent effect was
Table 1. IC50 Values of Known P2X Inhibitors Calculated Using Our HTS Assays against 1321N1-hP2X4, HEK293-hP2X4,
and HEK293-hP2X7 Cell Lines
cell line
1321N1-hP2X4 HEK-hP2X4 HEK-hP2X7
inhibitor IC50 [μM]
a IC50 [μM] 95% Cl [μM] IC50 [μM]
a IC50 [μM] 95% Cl [μM] IC50 [nM]
a IC50 [nM] 95% Cl [nM]
BX430 1.640 0.55 0.34−0.87 0.5435 1.3 1.2−1.5 N.A.
5-BDBD N.A. 5.7 4.3−6.7 1.236 9.2 8.4−10.0 N.A.
PSB12062 3.340 0.42 0.25−0.73 1.438 0.76 0.69−0.83 N.A.
AZ10606120 N.A. N.A. ∼10.037 92.0 81.0−103.0
aLiterature values.
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mitigated. After injection of crude venoms and agonist (10 μL
each), fluorescent Fura2-AM Ca2+-based (Figure 2A,B) or
YOPRO-1 (Figure 2C,D) dye uptake was measured as a
function of time.
Since venoms are complex mixtures of typically hundreds of
components that differ in concentration, we could not
predetermine the toxin concentrations used in the assays.
Thus, we performed our studies using a dilution series of
toxin fractions, which helped us to identify venoms/toxins with
higher or lower activity. Venom/toxin hits were defined as
those venoms/fractions that gave concentration-dependent
inhibition, at least 50% inhibition at the highest venom
concentration (10 μg/well), and whose activities were
confirmed upon retesting. The response for each crude
venom was plotted as a function of time and is shown in
Figure 2B and D. While venom SV7 did not show modulation
of hP2X4, the representative trace for one hit venom, SV1,
revealed a dose-dependent inhibition on 1321N1-hP2X4 with
10, 2, and 0.4 μg of crude venom yielding ∼69%, 27%, and 4%
inhibition, respectively (Figure 2A). The inhibitory effect was
validated and confirmed on HEK293-hP2X4 cells using the
YOPRO-1 uptake assay (Figure 2C). Notably, 10 μg of SV1
venom yielded 69−80% inhibition, which is similar to the
commercially available hP2X4 antagonist BX430 (75%
inhibition at 10 μM).
Fractionation of Crude Venom Hits. Following identi-
fication of crude venom hits, we then sought to deconvolute
the crude mixtures, as well as enhance the impact of minor
components in the assay,32 through the creation of fractionated
spider-venom product libraries. The crude venoms were
fractionated using C18 RP-HPLC, which separates compo-
nents on the basis of their relative hydrophobicity, with elution
monitored via absorbance at 214 and 280 nm (Figure 3). Most
active fractions from the first C18 RP-HPLC separation
contained multiple components, and therefore an additional
chromatography step was required to purify the hit compound.
This was often as simple as an additional C18 RP-HPLC
fractionation with a shallower gradient.
Discrete fractions were automatically collected based on
absorbance at 214 nm. The complexity of the crude of venoms
from L. klugi (Figure 3A), V. germanica (Figure 3B), C.
geographus (Figure 3C), and A. mellifera (Figure 3D), as judged
by the complexity of the RP-HPLC chromatograms, is
consistent with that reported previously for these spe-
cies.4,41−43 A total of 25−49 fractions covering the entire
elution profile were collected for each venom. Most fractions
represented only a small percentage of the overall venom
Figure 2. Screen of crude spider venoms against 1321N1-hP2X4 and HEK293-hP2X4. (A) Example showing the effect of spider venom 1 (SV1)
and 7 (SV7) and controls (buffer, ATP, and hP2X4-specific antagonist BX430) on 1321N1-hP2X4 and HEK-hP2X4 cells. While some spider
venoms showed concentration-dependent inhibition (e.g., SV1), some venoms, such as SV7, had no effect (A). To examine whether SV1 and SV7
have an effect on their own on P2X4, they were applied via the Flexstation 3 automated injection system alone without later application of the
P2X4 agonist ATP (this is denoted “Venom SV1//SV7 only”). (B) Kinetic responses for 1321N1-hP2X4. The inhibitory effect of one crude venom
(e.g., SV1) was confirmed via dose-dependent inhibition in the HEK293-hP2X4 YOPRO-1 assay (C) and the kinetic responses shown in panel
(D). Data points represent mean ± SD of three replicate experiments with triplicates on each plate except fraction injections. Significant differences
between the control (10 μM ATP) and the venom are indicated by * (P < 0.05) using one-way ANOVA followed by Dunnett’s test.
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profile, although less than six fractions from L. klugi spider
venom appeared to account for >75% of venom toxins.
A complicating fact in the HTS was that some venom
components yielded nonspecific calcium responses prior to
agonist application, and some wasp venoms, such as that from
V. germanica, interfered with fluorescent signal generation or
had cytotoxic pore-forming activity (Figure S2 in the
Supporting Information).44 Interference with fluorescence
signals represents a major challenge in assay development.
We found that venoms containing highly colored components
such as V. germanica (a number of yellow or red fractions were
obtained upon fractionation) could potentially generate
fluorescent signals. Fractions were subjected to a counter-
screen without cells and were found to emit fluorescence at the
tested wavelengths (340/380 excitation, 520 nm emission).
Therefore, venoms with these characteristics could not be
tested in these assays.
We believe some venom constituents to be concentrated
biogenic polyamines (spermine, spermidine), cytotoxic pep-
tides such as mellitin,45 or neurotransmitters such as histamine,
acetylcholine, and serotonin. Venom fractions containing these
compounds may modulate endogenously expressed receptors
in these cell lines such as ionotropic glutamate receptors46 or
GPCRs, and were thus considered nonspecific. Chelation of
calcium by venom components would likely manifest as a
reduction in extracellular calcium concentrations following
application into the well. Modifying the extracellular calcium
concentration 10-fold did not affect ATP-induced responses in
the HEK-hP2X4 cells (not shown).
Assay Hit Validation. Here, the inhibitory behavior
subsequently followed by agonist application was investigated.
The purified fractions obtained were subjected to fluorescent-
based bioassays on four stable cell lines: 1321N1-hP2X4,
HEK293-hP2X4, HEK293-hP2X3, and HEK293-hP2X7.
Figure 3. Representative RP-HPLC chromatograms showing fractionation of crude venoms from various venomous animals. (A) Bahia scarlet
tarantula (Lasiodora klugi); (B) Brazilian tarantula (Nhandu chromatus); (C) marine cone snail (Conus geographus); (D) German wasp (Vespula
germanica); (E) European honeybee (Apis mellifera); (F) Asian hornet (Vespa velutina nigrithorax). Venoms were fractionated on an analytical C18
RP-HPLC column (Jupiter 5 μm; Phenomenex), and components eluted at a flow rate of 1 mL/min using a gradient of solvent B (90% MeCN,
0.05% trifluoroacetic acid (TFA) in H2O) in solvent A (0.05% TFA in H2O) as indicated by the dotted lines. Absorbance was monitored at 214,
254, and 280 nm, but only the 214 nm absorbance is plotted here.
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Forty-eight fractions from Nhandu chromatus venom, initially
screened using 1321N1-hP2X4 (Ca2+ based Fura-2-AM assay,
Figure 4A), were further evaluated on HEK293-hP2X4
(YOPRO-1 dye uptake assay, Figure 4B), HEK293-hP2X7
(Figure 4C), and HEK293-hP2X3 (Figure 4D) in order to
both validate the fraction hits from the initial assay and test for
target selectivity. P2X positive and negative controls (ATP,
ivermectin,47 hP2X4-antagonist BX430;35 hP2X7-antagonists
AZ1060612037 and JNJ47965567;48 α,β-methylene ATP;49
and the hP2X3 antagonist purotoxin-1 [PT12)]) were included
as assay controls.
A comparison of the P2X3, P2X4, and P2X7 assays provided
some noteworthy inhibitory patterns. Ten of the 48 N.
chromatus fractions inhibited 1321N1-hP2X4 by >75% (Figure
4A), and nine of them were validated on the HEK293- hP2X4
cell line (Figure 4B), which corresponds to a 90% validation
rate. Fractions F39 and F42 from N. chromatus did not inhibit
hP2X3 (Figure 4D) or hP2X7 (Figure 4C), whereas other
fractions yielded inhibition of <20% (F10−F13, F40, F44,
F45) or even slight potentiation of hP2X3 (F5, F44). This
procedure further excluded several 1321N1-hP2X4 Fura-2-AM
hit fractions that we could not validate in the YOPRO-1
HEK293-hP2X4 assay (“false positive hits”) and hits that had
an inhibitory action on other P2X channels such as hP2X3 and
hP2X7 (“nonspecific hits”). Since the entry point for any drug
discovery program is generally the identification of modulators
with adequate and specific activity against the target of interest,
these initial hits from our screens provided a good starting
point to rapidly trace pharmacologically relevant compounds.49
This establishes our fluorescent Fura-2-AM and YOPRO-1
assays as effective for measuring the inhibitory action of venom
fractions on 1321N1-hP2X4.
Assay Specificity. After the initial screens of venom and
venom fractions, the precision, reproducibility, specificity, and
variability of the assays were evaluated. First, fractions F14,
F28, and F47 from N. chromatus venom, which had no effect
on any of the studied P2X receptors, were evaluated alongside
fraction F5, which inhibited hP2X4. This F5 toxin fraction
produced Ca2+ signals (Figure 5A) similar to YOPRO-1 dye
uptake signals (Figure 5B) and when compared to the negative
control (toxin F5 vs antagonist injection), which gave up to a
50-fold difference in signals, in both assays. However, when F5
was tested on HEK293-hP2X7, the difference between the
control (300 μM ATP) and F5 application was not statistically
significant (p > 0.05) (Figure 5C). These results confirm that
the assay is highly specific for identifying toxin hits against
hP2X4.
Assay Reproducibility. Within a compound screening
environment, it is a requirement that the assay is reproducible
across assay plates, screen days, and the duration of the entire
screening program.50 For that reason, we evaluated assay
reproducibility using the Z′ factor statistical method.51 This is
a common method for judging the quality of HTS assays, and
it has become the standard method of measuring assay quality
on a plate basis.15 The Z′ parameter considers not only the
signal window in the assay but also the variance around both
the high and low signals in the assay. Z′ ranges from 0 to 1; a
value of >0.4 is considered appropriately robust for compound
screening, although many industry groups prefer to work with
a Z factor of >0.6.15 We calculated the mean and SD for
positive [buffer + ATP] and negative [antagonist + ATP] wells
and used them to determine the Z′ factor. The experiment was
repeated once, and the averaged calculated Z′ factor for both
experiments on 1321N1-hP2X4, HEK293-hP2X4, and HEK-
hP2X7 cells was 0.57 ± 0.02 (CV 4.1%), 0.67 ± 0.032 (CV =
4.4%), and 0.56 ± 0.012 (CV = 2.2%), respectively. Our Z′
factors of >0.55 fall within the range expected for the robust
and reproducible assays.51 This indicates that our assays are
appropriate for HTS applications and that any plate or
systematic errors potentially affecting the assay were not
substantial.
Assay Variability. In addition to the Z factor, assay quality
is also determined by monitoring intra- and interplate
variability. Our data were compared to assess well-to-well
(intraplate) variability as well as plate-to-plate (interplate)
variability on six venom fractions and two controls (ATP,
antagonist) in three different experiments throughout one
month (see the text and Tables S1−3 in the Supporting
Information).
Figure 4. Screening of N. chromatus venom fractions using the (A)
1321N1-hP2X4 cell line, (B) HEK293-hP2X4 cell line, (C) HEK293-
hP2X7 cell line, and (D) HEK293-hP2X3 cell line. Fractions colored
red selectively inhibited hP2X4. The dash represents 100% hP2X4
activity as followed by 10 μM ATP application. Data points represent
mean ± SD of three replicate experiments, with triplicates on each
plate except fraction injections. Significant differences between the
positive control (ATP) and the fractions on either 1321N1-hP2X4 or
HEK293-hP2X4 cell line are indicated by * (P < 0.05) using one-way
ANOVA followed by Dunnett’s test.
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For the 1321N1-hP2X4 assay (Table S1), interplate
variability analysis yielded a mean CV of 9.98% (min: 6.43%,
max: 13.82%, median: 8.83%). The calculated intraplate
variability was 4.47% (min: 0.84%, max: 10.26%, median:
3.01%). For the HEK293-hP2X4 assay (Table S2), interplate
variability analysis yielded a mean %CV of 13.59% (min:
11.68%, max: 14.97%, median: 14.13%). The calculated
intraplate variability was 4.94% (min: 1.66%, max: 7.52%,
median: 5.25%). For the HEK293-hP2X7 assay (Table S3),
interplate variability analysis yielded a mean %CV of 14.88%
(min: 12.88%, max: 17.49%, median: 14.82%). The calculated
intraplate variability was 5.22% (min: 2.61%, max: 6.07%,
median: 5.68%). Variability across the same plates was
therefore low (<5%), and as many of the venom libraries to
be tested would be measured on a single plate, this means that
hit fractions can be identified with good accuracy.
Assay quality can also be monitored through the inclusion of
pharmacological controls within each assay. Data for the
controls (ATP and antagonist) fell within a predefined limit
(CV = 1.9−5.3%), and thus the variability is deemed
acceptable. Another quality control measure was the stability
of the fractions used in these studies. The refrigerated samples
used in these studies remained stable for the duration of the
study (one month), as judged using RP-HPLC (data not
shown). The results presented therefore indicate that our
fluorescent-based assays provide a rapid and sensitive method
for HTS screening of venoms and suggest that the assays can
be adapted to other natural products screenings.
■ SUMMARY
With recent advances in laboratory automation and HTS and
MS methods, the use of venom and toxins as input into high-
throughput assays has undergone a renaissance. Convergence
of modern natural product isolation methods with chemical
genomics and bioinformatics thus promises to further advance
the rapid identification of potent natural products with novel
mechanisms of action. Though a cell-based HTS may initially
appear daunting, there are many targets for which a cell-based
screen represents the fastest and cheapest path to lead
generation.49 Furthermore, the two drivers for innovation in
cell-based HTS methodologies are the need to miniaturize the
assay volumes to 96-, 384-, and 1536-well format and the
desire to capture temporal and spatial data on target activity.32
The HTS strategy we have developed for identifying P2X
modulators from animal venoms provides a powerful tool in
the hit generation process. Arranging venoms and venom
fractions into 96-well plates allows for rapid screening of
hundreds of samples, in principle, against multiple receptor
targets.
In order to screen large chemical libraries (>104
compounds), these assays would need to be scaled-up to suit
higher density formats such as 1536- or 3456-well plates.
Higher density formats in combination with dedicated robotic
workstations would make screening of large libraries highly
feasible. Still, the P2X screens we developed provide a reliable,
sensitive, and specific method for HTS assessment of venom
fractions against hP2X3, hP2X4, and hP2X7. Using these
assays, we first demonstrated that our HTS strategy allows
screening of multiple targets, which provides significant cost
and time savings. Second, the advantage of spending time to
generate relatively pure natural products from a library is that it
provides a more meaningful comparison between targets at
early stages of the drug discovery process. Third, fractionation
of the venoms allowed us to discriminate between fractions
that are broadly cytolytic from those with a specific effect on a
particular target. Finally, the majority of validated hits against
hP2X4 were derived from spider venoms, further emphasizing
the rich pharmacological diversity of this class of natural
products.52−54 The availability of new and specific modulators
from multiple chemical classes will be useful in understanding
the biochemical, physiological, and clinical implications of
venom toxins as well as providing functional insight into the
P2X receptor family. In future work we aim to isolate and
characterize new P2X inhibitors from these venomous animals
in order to accelerate drug discovery in the purinergic field.
■ EXPERIMENTAL SECTION
Materials. Lyophilized hymenopteran venoms (species reported in
Supporting Information, Table S4) were purchased from either
Alphabiotoxine or Venomtech. Cone snail venoms were supplied by
BioConus. Centipede venoms were provided by Dr. Eivind Undheim
(The University of Queensland, Australia) and Dr. Ian Mellor
(University of Nottingham, UK). All arachnid venoms were provided
by Dr. Volker Herzig and Professor Glenn King (The University of
Queensland) or were obtained from Alphabiotoxine. All other
reagents were purchased from commercial sources and were of the
highest purity commercially available.
Figure 5. Assay specificity. To assess assay specificity, commercially available compounds (BX430, PSB12062, AZ10606120, IVM) that are known
to modulate hP2X4 and hP2X7 and inactive venom fractions (F14, F28, F47) were tested for a response in the (A) Fura-2 1321N1-hP2X4, (B)
YOPRO-1 HEK293-hP2X4, and (C) YOPRO-1 HEK293-hP2X7 assays, together with a hit venom fraction (F5). In order to calculate the Z′ factor,
data were collected over a period of one month with three experiments performed on different days and eight replicates per plate. Data points
represent mean ± SD of three replicate experiments with triplicates on each plate except fraction injections. Significant differences between the
control (ATP) and the venom are indicated by * (P < 0.05) using one-way ANOVA followed by Dunnett’s test.
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Cell Cultures and Establishments of Stable Cell Lines.
Human astrocytoma 1321N1 cells stably expressing hP2X4 were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Bio-
Whittaker) containing 10% (v/v) fetal bovine serum (FBS), 100 U/
mL penicillin, 100 μg/mL streptomycin (Fisher Scientific), and 400
μg/mL G418 (HelloBio). HEK293 cells stably expressing either
hP2X3, hP2X4, or hP2X7 were maintained under the same condition
in DMEM/F12 media (Gibco). The 1321N1-hP2X4 and HEK293-
hP2X3 stable cell lines were generated by chemical transfection using
Lipofectamine 2000 and plasmids encoding either hP2X3 or hP2X4.
The hP2X3 plasmid was a kind gift from Dr. Lin-Hua Jiang
(University of Leeds). Stable clones were selected using a positive
selection marker (G418, 800 μg/mL). G418-resistant clones were
further selected according to the strength of their ATP-induced
increase in intracellular calcium ([Ca2+]I). All cells successfully
expressing the receptor of interest were then expanded. All cells were
maintained at 37 °C with 5% CO2 in a humidified incubator; P2X
expression remained stable for at least 25−30 passages. All 96-well
plates (Nunc catalogue number 167008, Fisher Scientific) were
coated in-house with poly-D-lysine (Merck Millipore) at a
concentration of 50 μg/mL.
[Ca2+]I Measurements (for Fura-2 AM Assay). One day prior to
measurements, 1321N1-hP2X4 cells were plated onto poly-D-lysine-
coated 96-well plates at 2 × 104 cells/well. After 24 h, the cells were
loaded for 1 h at 37 °C with 2 μM Fura-2 AM in Hank’s Balanced Salt
Solution (HBSS, Gibco). The Fura-2 loading buffer dye was removed;
then the cells were incubated in 80 μL of Etotal buffer, containing (in
mM) 145 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 13 D-glucose, 10 HEPES;
pH 7.33. Some of the compounds (IVM and/or BX430) were either
pretreated with cells for 10 min or applied (crude venoms and
fractions) before [Ca2+]I measurements on a Flexstation 3 (Molecular
Devices) at 37 °C. The injection volume was 10 μL with 150 μL
pipette height and rate of 4 (∼62 μL/s). The run time was 300 s with
3.5 s intervals and 3 reads/well. The change in [Ca2+]i concentration
was calculated as the ratio of Fura-2 intensities at 520 emission from
excitation at 340 and 380 nm (F ratio).
[Ca2+]I Measurements (for FLIPR Calcium 6 Assay). One day
prior to measurements, HEK293-hP2X3 cells were plated on poly-D-
lysine-coated 96-well plates (Nunc catalogue number 167008, Fisher
Scientific) at a concentration of 2 × 104 cells/well. After 24 h, the cells
were loaded with the no-wash calcium-sensitive dye Calcium 6 using
the FLIPR Calcium 6 assay kit (Molecular Devices) and incubated for
2 h prior to measurements on a Flexstation 3 (Molecular Devices) at
37 °C. The dye was diluted 1:3 in buffer containing (in mM) 145
NaCl, 5 KCl, 0.1 CaCl2, 13 D-glucose, and 10 HEPES; pH 7.35. The
excitation and emission wavelengths were 485 and 525 nm,
respectively, with 3 reads/well and a 1.3 s interval.
YOPRO-1 Dye Uptake Measurements. This method was
adapted and further optimized from Patrice et al.50 One day prior
to measurements, HEK293-hP2X4 and HEK293-hP2X7 cells were
plated on poly-D-lysine-coated 96-well plates at 2 × 104 cells/well.
After 24 h, the culture media was aspirated, and 80 μL of YOPRO-1
assay buffer (145 mM NaCl, 5 mM KCl, 0.1 mM CaCl2, 13 mM D-
glucose, 10 mM HEPES; pH 7.35) with 2 μM YOPRO-1 was applied.
Some of the compounds (IVM and/or BX430) were either
preincubated with cells for 10 min or applied (crude venoms and
fractions) before the measurements took place at 37 °C using a
Flexstation 3 (Molecular Devices). The injection volume was 10 μL
with a 150 μL pipet height and rate of 4 (∼62 μL/s). The run time
was 300 s with a 3.9 s interval, 6 reads/well, and 77 reads in total.
Measurement parameters were as follows: bottom reading, excitation
wavelength (490 nm), emission wavelength (520 nm).
Isolation, Purification, and Mass Analysis of Venom
Fractions. Venom (1 mg) was diluted with H2O, sterile filtered
(0.22 μm; Merck Millipore), then loaded onto an analytical C18 RP-
HPLC column (Jupiter 4.6 × 250 mm, 5 μm, 300 Å; Phenomenex)
attached to an Agilent HPLC system. Components were eluted at 1
mL/min using isocratic elution at 5% solvent B (90% acetonitrile
(MeCN), 0.05% trifluoroacetic acid (TFA) in H2O) for 5 min
followed by a gradient of solvent B in solvent A (0.05% TFA in H2O):
5−20% over 5 min; 20−40% over 40 min; 40−80% over 5 min; 80−
100% over 5 min. Absorbance was measured at 214, 254, and 280 nm
using a UV detector (Shimadzu). Individual fractions were
lyophilized, resuspended in 100 μL of H2O, and further purified
using the same RP-HPLC system. Matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF MS) was
performed on an Applied Biosystems 4700 Proteomics analyzer. The
toxin fractions eluted from RP-HPLC were dissolved in 100−150 μL
of H2O; then 2 μL was mixed with 2 μL of 10 mg/mL α-cyano-4-
hydroxycinnamic acid (CHCA) matrix dissolved in 50% MeCN, 50%
H2O, and 0.1% TFA. Toxins were then lyophilized in H2O and stored
at −20 °C until further studies.
Assay Specificity. To assess assay specificity, we examined the
response evoked by commercially available hP2X4 modulators
(BX430, PSB12062, IVM), together with three fractions (F8, F28,
F47) from N. chromatus venom that were not identified as hits in our
initial assay. The positive control was a hit fraction (F5) from the
same venom.
Assay Variability. Interplate and intraplate variability were
evaluated using eight venom fractions in three different experiments.
Venom fractions were prepared as described above and stored at 4 °C
for the duration of the study. Each prepared fraction was tested on
three different days, with eight replicates per plate. Eight replicates of
positive controls (ATP), eight replicates of negative controls (buffer,
antagonist), and eight replicates of a positive allosteric modulator
(IVM) were included on each plate. Coefficients of variation were
calculated using normalized results for each fraction by expressing the
venom-fraction signal as a fraction of the averaged positive control
signal from the same plate. For intraplate variability, unadjusted signal
values were used to calculate variability between replicates for each
fraction on a plate.
Assay Reproducibility. Assay reproducibility was assessed using
the Z′ factor statistical method. This parameter assesses, in part, assay
quality by calculating separation between positive and negative
signals. Z′ values of 0.5−1.0 indicate a high level of reproducibility,
whereas Z′ values of 0−0.5 indicate a less robust assay. The Z′ factor
was calculated using the following formula:51
σ
μ μ
= − × +
−
Z factor 1
3 ( P2X positive P2X negative)
( P2X positive P2X negative)
The Z′ experiment was performed twice with positive and negative
controls (ATP and buffer, respectively) that were used throughout the
assay development. In the first experiment, 60 positive controls
(ATP) and 36 negative controls (hP2X4/hP2X7 antagonist) were
tested. In the second experiment, 48 positive controls (ATP) and 48
negative controls (hP2X4/hP2X7 antagonist) were tested.
Data Analysis. GraphPad v. 8.0 was used to analyze data collected
from the Flexstation 3 using SoftMax Pro v5.4 software; the baseline
read delay was set to zero. Data are reported as mean ± SD, except
where otherwise specified. For two groups, a paired t-test was
performed. In the case of more than two groups, one-way ANOVA
with multiple comparison (Dunnett’s post-test with ATP as the
control sample) was used.
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Jimeńez-Vargas, J. M.; Possani, L. D.; Zare, R. N. J. Nat. Prod. 2018,
81, 1899.
(10) King, G. F. Expert Opin. Biol. Ther. 2011, 11, 1469.
(11) Holford, M.; Daly, M.; King, G. F.; Norton, R. S. Science 2018,
361, 842.
(12) Yu, H.-b.; Li, M.; Wang, W.-p.; Wang, X.-l. Acta Pharmacol. Sin.
2016, 37, 34.
(13) Santos, R.; Ursu, O.; Gaulton, A.; Bento, A. P.; Donadi, R. S.;
Bologa, C. G.; Karlsson, A.; Al-Lazikani, B.; Hersey, A.; Oprea, T. I.;
Overington, J. P. Nat. Rev. Drug Discovery 2017, 16, 19.
(14) Dunlop, J.; Bowlby, M.; Peri, R.; Vasilyev, D.; Arias, R. Nat.
Rev. Drug Discovery 2008, 7, 358.
(15) Macarron, R.; Banks, M. N.; Bojanic, D.; Burns, D. J.; Cirovic,
D. A.; Garyantes, T.; Green, D. V.; Hertzberg, R. P.; Janzen, W. P.;
Paslay, J. W.; Schopfer, U.; Sittampalam, G. S. Nat. Rev. Drug
Discovery 2011, 10, 188.
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